Go to article: Home | ‘Right shoring’ API production in EuropeGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: HOF SonderanlagenbauGo to article: BEA TechnologiesGo to article: CommentGo to article: 4D Molecular’s Fabry gene therapy program on FDA clinical holdGo to article: Price is key for wider market adoption of Amgen’s AmjevitaGo to article: Wegovy: the latest weight loss fadGo to article: PROTAC development gains momentum, but clinical performance is poorGo to article: FDA head Califf on tighter accelerated approvals and lower drug pricesGo to article: In DepthGo to article: ‘Right shoring’ API production in EuropeGo to article: Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?Go to article: DCTs in 2023: New year’s resolutions for decentralised clinical trialsGo to article: Inside the hunt for an Alzheimer’s disease vaccineGo to article: Are we entering the era of biologics for COPD?Go to article: CMO Moves: Regulatory catalysts for drug manufacturing – FebruaryGo to article: EventsGo to article: Next issue